Eltrombopag/eltrombopag dose adjustment and discontinuation guidelines

Eltrombopag/Eltrombopag is an important oral drug widely used in the treatment of immune thrombocytopenia, aplastic anemia, and thrombocytopenia associated with chronic hepatitis C infection. It helps correct thrombocytopenia caused by a variety of diseases by stimulating the production of platelets in the bone marrow, thereby controlling disease progression. However, it is important to note that eltrombopag primarily acts to control, not cure, the disease.

When using eltrombopag, your doctor will adjust the dose based on the patient's response to treatment. Typically, treatment is started with a lower daily dose, such as 12.5 mg or 25 mg, and the dose is gradually increased to ensure that the platelet count is maintained above at least 50,000/mm, thereby reducing the risk of bleeding.

The specific dose adjustment strategy is as follows: If the patient's platelet count is lower than50,000/mm, the doctor will consider gradually increasing the dose of eltrombopag until it reaches the lowest level to maintain the platelet count, but the maximum dose should not exceed 75 mg per day. When the patient's platelet count is between 50,000/mm and 200,000/mm, it is recommended to maintain the current dose. If the platelet count further rises to between 200,000/mm and 400,000/mm, a dose reduction of 25 mg per day should be considered; for patients already taking a 25 mg dose, the dose should be reduced to 12.5 mg per day.

When a patient's platelet count exceeds400,000/mm, it is recommended to suspend the use of eltrombopag and closely monitor the platelet count twice a week. Once the platelet count drops below 150,000/mm, consideration may be given to resuming the patient's daily dose, but at a 25 mg reduction; for patients originally taking 25 mg, the patient should be restored to a daily dose of 12.5 mg.